Nabi Biopharmaceuticals (NASDAQ:NABI)

CAPS Rating: 4 out of 5

The Company leverage its experience and knowledge in powering the human immune system to develop and market products that target serious medical conditions in the areas of transplantation, infectious disease and hematology/oncology.

Recs

0
Player Avatar snapper99man (65.33) Submitted: 2/11/2010 7:40:19 PM : Outperform Start Price: $5.07 NABI Score: -92.31

Nic-Vax is gonna hit..they are the closet to getting it done....gsk will take most of the prfits...but this company may 5 bag...

Featured Broker Partners


Advertisement